DHHC enzymes in alphavirus glycoprotein acylation: A target for broad-spectrum antiviral therapy

Le résumé fourni par la source

Alphaviruses are mosquito-transmitted viruses that cause severe zoonotic diseases. Their envelope glycoproteins, E1 and E2, undergo cysteine acylation, a process critical for virus infection but previously undefined mechanistically. Using the Getah virus as a model, we found that E1 is acylated at Cys433 in the endoplasmic reticulum (ER), a modification beneficial for virus entry. E2 follows a unique stepwise acylation pattern: Cys385 is acylated in the ER, while Cys395, Cys415, and Cys416 undergo interdependent acylation in the Golgi. Palmitoylation of E2 Cys415/416 proved essential for budding. Acylation also facilitated cholesterol incorporation into virions independently of lipid rafts. A small interfering RNA (siRNA) screen identified distinct acyltransferases for E1 and compartment-specific enzymes for E2. Depletion of Golgi-localized Asp-His-His-Cys (DHHC)11, which modifies Cys415/416, significantly inhibited replication of multiple alphaviruses. This study establishes the spatiotemporal model of alphavirus glycoprotein acylation and identifies DHHC11 as a conserved target for pan-alphavirus therapeutics, with potential implications for reducing the public health burden of alphavirus infections.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.